CN1207033C - Traditional Chinese medicine composition for curing wind-heat type cold and its preparing method - Google Patents
Traditional Chinese medicine composition for curing wind-heat type cold and its preparing method Download PDFInfo
- Publication number
- CN1207033C CN1207033C CNB031001882A CN03100188A CN1207033C CN 1207033 C CN1207033 C CN 1207033C CN B031001882 A CNB031001882 A CN B031001882A CN 03100188 A CN03100188 A CN 03100188A CN 1207033 C CN1207033 C CN 1207033C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- pharmaceutical composition
- herba
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 title abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 238000004821 distillation Methods 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 241000207929 Scutellaria Species 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 88
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 241000628997 Flos Species 0.000 claims description 23
- 239000000796 flavoring agent Substances 0.000 claims description 21
- 235000019634 flavors Nutrition 0.000 claims description 21
- 210000000582 semen Anatomy 0.000 claims description 20
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 239000012141 concentrate Substances 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 238000004321 preservation Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- 230000006837 decompression Effects 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- -1 correctives Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 241000245240 Lonicera Species 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 235000008216 herbs Nutrition 0.000 abstract 3
- 201000009240 nasopharyngitis Diseases 0.000 abstract 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000001405 Artemisia annua Nutrition 0.000 abstract 1
- 240000000011 Artemisia annua Species 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 241000576429 Forsythia suspensa Species 0.000 abstract 1
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 235000006751 Platycodon Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 241000951473 Schizonepeta Species 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229930189914 platycodon Natural products 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 description 29
- 239000006188 syrup Substances 0.000 description 29
- 206010011224 Cough Diseases 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 22
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 18
- 229910052709 silver Inorganic materials 0.000 description 18
- 239000004332 silver Substances 0.000 description 18
- 230000036760 body temperature Effects 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 235000008504 concentrate Nutrition 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 6
- 230000000954 anitussive effect Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000001754 anti-pyretic effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 208000037386 Typhoid Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 201000008297 typhoid fever Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000002155 anti-virotic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000011533 mixed conductor Substances 0.000 description 3
- 231100000028 nontoxic concentration Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000011951 anti-virus test Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000252870 H3N2 subtype Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 241001662443 Phemeranthus parviflorus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 231100001134 median toxic concentration Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02G—INSTALLATION OF ELECTRIC CABLES OR LINES, OR OF COMBINED OPTICAL AND ELECTRIC CABLES OR LINES
- H02G11/00—Arrangements of electric cables or lines between relatively-movable parts
- H02G11/02—Arrangements of electric cables or lines between relatively-movable parts using take-up reel or drum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
- B65H75/00—Storing webs, tapes, or filamentary material, e.g. on reels
- B65H75/02—Cores, formers, supports, or holders for coiled, wound, or folded material, e.g. reels, spindles, bobbins, cop tubes, cans, mandrels or chucks
- B65H75/34—Cores, formers, supports, or holders for coiled, wound, or folded material, e.g. reels, spindles, bobbins, cop tubes, cans, mandrels or chucks specially adapted or mounted for storing and repeatedly paying-out and re-storing lengths of material provided for particular purposes, e.g. anchored hoses, power cables
- B65H75/38—Cores, formers, supports, or holders for coiled, wound, or folded material, e.g. reels, spindles, bobbins, cop tubes, cans, mandrels or chucks specially adapted or mounted for storing and repeatedly paying-out and re-storing lengths of material provided for particular purposes, e.g. anchored hoses, power cables involving the use of a core or former internal to, and supporting, a stored package of material
- B65H75/40—Cores, formers, supports, or holders for coiled, wound, or folded material, e.g. reels, spindles, bobbins, cop tubes, cans, mandrels or chucks specially adapted or mounted for storing and repeatedly paying-out and re-storing lengths of material provided for particular purposes, e.g. anchored hoses, power cables involving the use of a core or former internal to, and supporting, a stored package of material mobile or transportable
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
- B65H75/00—Storing webs, tapes, or filamentary material, e.g. on reels
- B65H75/02—Cores, formers, supports, or holders for coiled, wound, or folded material, e.g. reels, spindles, bobbins, cop tubes, cans, mandrels or chucks
- B65H75/34—Cores, formers, supports, or holders for coiled, wound, or folded material, e.g. reels, spindles, bobbins, cop tubes, cans, mandrels or chucks specially adapted or mounted for storing and repeatedly paying-out and re-storing lengths of material provided for particular purposes, e.g. anchored hoses, power cables
- B65H75/38—Cores, formers, supports, or holders for coiled, wound, or folded material, e.g. reels, spindles, bobbins, cop tubes, cans, mandrels or chucks specially adapted or mounted for storing and repeatedly paying-out and re-storing lengths of material provided for particular purposes, e.g. anchored hoses, power cables involving the use of a core or former internal to, and supporting, a stored package of material
- B65H75/44—Constructional details
- B65H75/4457—Arrangements of the frame or housing
- B65H75/4468—Tubular frame
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
- B65H2301/00—Handling processes for sheets or webs
- B65H2301/50—Auxiliary process performed during handling process
- B65H2301/51—Modifying a characteristic of handled material
- B65H2301/514—Modifying physical properties
- B65H2301/5144—Cooling
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01B—CABLES; CONDUCTORS; INSULATORS; SELECTION OF MATERIALS FOR THEIR CONDUCTIVE, INSULATING OR DIELECTRIC PROPERTIES
- H01B7/00—Insulated conductors or cables characterised by their form
- H01B7/42—Insulated conductors or cables characterised by their form with arrangements for heat dissipation or conduction
- H01B7/421—Insulated conductors or cables characterised by their form with arrangements for heat dissipation or conduction for heat dissipation
- H01B7/426—Insulated conductors or cables characterised by their form with arrangements for heat dissipation or conduction for heat dissipation using cooling fins, ribs
Landscapes
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Storing, Repeated Paying-Out, And Re-Storing Of Elongated Articles (AREA)
Abstract
The present invention discloses a traditional Chinese medicinal composition for treating wind-heat common cold and a preparation method thereof. The composition is composed of bupleurum roots, honeysuckle flowers, scutellaria, kudzuvine roots, fineleaf schizonepeta herbs, sweet wormwood herbs, weeping forsythia capsules, platycodon roots, bitter apricot seeds, mint and heartleaf houttuynia herbs. When the traditional Chinese medicinal composition is prepared, the methods of distillation, decoction and alcohol extraction are adopted to different ingredients to achieve the full exertion of effective medicines. The composition has good effect on the treatment of the wind-heat common cold.
Description
Invention field
The present invention relates to a kind of Chinese medicine composition, particularly be used for the treatment of the Chinese medicine composition of anemopyretic cold.
Background technology
Anemopyretic cold is one of human modal disease, and the sickness rate height easily causes other diseases such as myocarditis, has brought inconvenience for people's live and work.
Flu is the common exogenous diseases that causes because of ailment said due to cold or exposure invasion and attack human body.The record of relevant flu sees " interior warp " the earliest, " element is asked the bone empty talk " " wind from outside go into, make us cold with shivering, sweating headache, heavy sensation of the body aversion to cold ".Having illustrated that flu is mainly due to the diseases caused by exogenous pathogenic factor ailment said due to cold or exposure, this says with " element asks lunar sun bright opinion ": the viewpoint of " hinder in the wind person, on be subjected to it earlier " is consistent.Later Han Dynasty's Zhang Zhongjing is divided into exterior deficiency syndrome, exterior excess syndrome to the diseases caused by exogenous pathogenic factor exterior syndrome in " Treatise on Febrile Diseases is distinguished sun abnormal pulse card and controls ", for theoretical basis has been established in the dialectical treatment of flu.Sui Dynasty " disorder of QI duke or princess under an emperor during the General Treatise on the Cause and Symptoms of Diseases " has been done deep argumentation to the cause of disease and the feature of flu." all infectionss source is waited the opinion wind heat and waited " has certain description to the origin cause of formation and the Clinical symptoms of affection due to external wind and heat again.Yuan Dynasty's " danxi's experiential therapy invasion by pathogenic cold appendix " has proposed flu to be thought by mistake the ring of typhoid fever, and the hot temperature of treatment flu, hot cool two big rules." the attached wind of Wanbing Huichun, Curative Measures for All Diseases typhoid fever " is pointed out: " pestilent cold wind and cold person should be induced sweat also." point out inducing diaphoresis to expel pathogens treatment flu.Outside " card is controlled to converge and mended cold " the exorcising invasion and attack of pointing out to catch a cold, also relevant with the power and the disposition of body constitution.Ye Tianshi points out " warm pathogen tend to attack the upper orifices, the first-selected lung of violating ".In sum, Gan Mao the cause of disease to be experiencing ailment said due to cold or exposure as can be known, but normal relevant closely with human righteousness's power.The flesh table is mainly defended at lung in its sick position, and treatment should be dispersed to induce sweat, and dialectically should at first distinguish wind and cold, wind-heat syndrome, also should belong to void, true according to body constitution and symptom performance then, and treatment is a rule with relieving the exterior syndrome with drugs of pungent in flavor and warm in nature and relieving the exterior syndrome with drugs of pungent in flavor and cool in nature mainly.
Summary of the invention
One object of the present invention is to disclose a kind of Chinese medicine composition of new treatment anemopyretic cold; Another object of the present invention is the method for a kind of new treatment anemopyretic cold Chinese medicine composition of open preparation.
The crude drug of pharmaceutical composition of the present invention is formed and proportioning following (by weight):
Radix Bupleuri 50-150 weight portion Flos Lonicerae 40-110 weight portion Radix Scutellariae 30-90 weight portion
Radix Puerariae 25-75 weight portion Herba Schizonepetae 25-75 weight portion Herba Artemisiae Annuae 40-110 weight portion
Fructus Forsythiae 40-110 weight portion
The crude drug that also can add following component in the crude drug of pharmaceutical composition of the present invention:
Semen Armeniacae Amarum 25-75 weight portion Herba Menthae 40-110 weight portion Herba Houttuyniae 40-110 weight portion.
Also can add Radix Platycodonis 25-75 weight portion in the crude drug of pharmaceutical composition of the present invention.
The crude drug of pharmaceutical composition of the present invention is formed and proportioning can also be (by weight):
Radix Bupleuri 80-120 weight portion Flos Lonicerae 60-90 weight portion Radix Scutellariae 50-70 weight portion
Radix Puerariae 40-60 weight portion Herba Schizonepetae 40-60 weight portion Herba Artemisiae Annuae 60-90 weight portion
Fructus Forsythiae 60-90 weight portion Semen Armeniacae Amarum 40-60 weight portion Herba Menthae 60-90 weight portion
Herba Houttuyniae 60-90 weight portion Radix Platycodonis 40-60 weight portion
The optimum weight proportioning of above-mentioned raw materials is:
Radix Bupleuri 100 weight portion Flos Loniceraes 75 weight portion Radix Scutellariaes 60 weight portions
Radix Puerariae 50 weight portion Herba Schizonepetae 50 weight portion Herba Artemisiae Annuaes 75 weight portions
Fructus Forsythiae 75 weight portion Semen Armeniacae Amarums 50 weight portion Herba Menthaes 75 weight portions
Herba Houttuyniae 75 weight portion Radix Platycodoniss 50 weight portions
According to the preparation process of routine, above-mentioned raw materials can be prepared into clinical medicine dosage form commonly used, for example: pill, tablet, granule, oral liquid, capsule, unguentum, Emulsion, masticatory, injection and middle medicine film etc.
Medicine of the present invention also can add conventional drug excipient as required, as solvent, disintegrating agent, correctives, antiseptic, coloring agent, dispersant, binding agent, thickening agent, lubricant, diluent etc.
This preparation of drug combination method:
More than ten simply, get Semen Armeniacae Amarum and be broken for coarse granule, with seven flavors such as Radix Bupleuri, Flos Lonicerae, Herba Artemisiae Annuae, Fructus Forsythiae, Herba Schizonepetae, Herba Menthae, Herba Houttuyniae, soaked 1-2 hour, add thermal distillation, collect distillate and distill again, collect re-distilled liquid device preservation in addition, three flavors such as medicinal residues and Radix Scutellariae, Radix Puerariae, Radix Platycodonis merge, decoct with water 3-4 time, each 1-3 hour, the medicinal liquid after decocting liquid and the above-mentioned distillation merged, filter, filtrate concentrates; Add ethanol, stir evenly, cold preservation 22-26 hour, get the supernatant decompression recycling ethanol, add above-mentioned re-distilled liquid, at last directly or add pharmaceutically acceptable excipient and make clinical acceptable forms through conventional operation, as tablet, oral liquid, capsule, granule etc.
The present composition has well antibacterial, antivirus action, and being used for the treatment of diseases such as heating due to affection due to external wind and heat, influenza, the viral influenza etc., cough has curative effect preferably, and said composition toxicity is very little, and clinical practice is safe and reliable.
The present composition is external to have tangible bacteriostasis to the respiratory tract common pathogen, and influenza virus first and second amphitypys are all had tangible antivirus action.Rat, rabbit are all shown tangible antipyretic effect, mice, Cavia porcellus are had tangible antitussive effect.The mice nonspecific immunity there is obvious facilitation.Following experimental example is used to further specify the present invention.Following experiment material and method all are applicable to each experimental example.
One. experiment material: 1. be subjected to the reagent thing: present composition preparation (bavin silver oral liquid, be compound preparation). Chinese medicine institute system chamber, Shandong provides, every contains crude drug in whole 7.35g/10ml, press the desired concn dilution during experiment. lot number: 960216. cold treating and cough relieving syrups, Yulin Pharmaceutic Factory, Gangxi Autonomous Region's product, lot number: 951021; 2 animals: mice, the Kunming kind, Shandong Province's medical experiment animal center provides, the quality certification number, the real kinoplaszm word in Shandong: 950101. rat Wistar kinds, Shandong Medical University's Experimental Animal Center, the real kinoplaszm word in quality certification Shandong: 950102. Cavia porcelluss: epidemic prevention station animal housing in Shandong Province's provides, quality certification Shandong kinoplaszm word: 950105.
Two. experimental technique and result: by " provisions for new drugs approval " requirement, carry out the main pharmacodynamics laboratory observation with reference to " new Chinese medicine preclinical study guideline (exposure draft) ", the result is by T or X
2A statistical is organized in check.
Experimental example 1Eliminating evil effect
1.1 antibacterial tests: experimental therapeutical effect in the 1.1.1 animal body: 64 of body weight 20-22g mices, ♂ ♀ half and half, be divided into four groups at random, each 8 of every group of ♂ ♀, behind the grouping 24h, give bavin silver-colored oral liquid 3.68g/kg respectively, 7.36g/kg (dosage is calculated by containing primary dose), wherein the 3.68g/kg group is administration after bavin silver oral liquid is diluted a times.Cold treating and cough relieving syrup 7.36g/kg, matched group are with capacity water, and the administration capacity all is 0.2ml/kg.Behind the administration 24h,, give every ml bacteria containing amount 2.5 * 10 according to the trial test result
85% yeast mixture, every 10g0.2ml.ip. strain is Diplococcus pneumoniae ATC025014, bacterium liquid is provided by epidemic prevention station strain chamber, Shandong Province Sun Qi China technologist-in-charge, and assists experiment.Simultaneously still give medicine ig, once a day, administration is 4 times altogether.Observe the dead mouse situation, result such as table 1, X
2Statistics between check is organized.
The protective effect of table 1 pair Diplococcus pneumoniae infecting mouse
Group dosage Mus number
Death tollGeneral mortality rate %
24h 48h
Water contrasts 16 4 13 92.86
Oral liquid 3.68 16 15 31.25
Oral liquid 7.36 16 13 18.75
Syrup 7.36 16 26 32.5
Visible bavin silver oral liquid of experimental result and cold treating and cough relieving syrup have significant protective effect to the Diplococcus pneumoniae infecting mouse, reduce mortality rate in its 48 hours, and 48h-7 days, each was organized mice and does not all occur dead again.
1.1.2 extracorporeal bacteria inhibitor test (mensuration of minimal inhibitory concentration MIC): adopt the test tube doubling dilution to carry out bavin silver oral liquid and cold treating and cough relieving syrup measurement result such as table 2 to the minimal inhibitory concentration MLC of respiratory tract common pathogen by epidemic prevention station strain chamber, Shandong Province Cui Shu jade, Sun Qi China technologist-in-charge:
The MLC (minimal inhibitory concentration) of table 2 pair respiratory tract common pathogen
Bacterial strain bavin silver oral liquid cold treating and cough relieving syrup
Hemolytic hammer 1: 4 (-) 1: 8 (-) 1: 16 (-) 1: 32 (+) 1: 4 (-) 1: 8 (-) 1: 16 (-) 1: 32 (+)
Diplococcus pneumoniae 1: 4 (-) 1: 8 (-) 1: 16 (+) 1: 4 (-) 1: 8 (+)
Staphylococcus aureus 1: 4 (-) 1: 8 (-) 1: 16 (-) 1: 32 (+) 1: 4 (-) 1: 8 (+)
Escherichia coli 1: 2 (-) 1: 4 (-) 1: 16 (+) 1: 1 (-) 1: 2 (+)
Visible bavin silver oral liquid of experimental result and syrup are to the certain bacteriostasis of respiratory tract common pathogen performance.
1.2 antivirus test
1.2.1 experimental treatment in the animal body: 64 of body weight 20-22g mices, ♂ ♀ half and half, be divided into four groups at random, the grouping administration behind the first administration 24h, according to trial test gives LD90 influenza A virus H3N2 diseased plant behind the rechallenge 30min with 1.1, collunarium, (every Mus is dripped 10ul), this experiment virus are provided by sanitary system virusology teaching and research room of Shandong Medical University, Han Guangbin, defend beautiful lecturer and assist to experimentize.Give the virus back and continue administration, once a day, successive administration 4 days is observed and the record different time is respectively organized the infected mice mortality rate, and result such as table 3 are by X
2Check is compared between organizing.
Table 3, bavin silver oral liquid is to the protective effect of influenza virus infecting mouse
Group dosage (g/kg) Mus number
Death tollGeneral mortality rate (%)
24 48 72 96 sums
Contrast 16 4470 15 93.75
Oral liquid 3.68 16 13408 50.00
Oral liquid 7.36 16 01405 31.25
Syrup 7.36 16 22408 50
Respectively organize infected mice after 72 hours and occur death again, the visible bavin silver of experimental result oral liquid has significant protective effect to the influenza virus infecting mouse, obviously reduces its mortality rate.
1.2.2 extracorporeal antivirus effect test: by Shandong Medical University's sanitary system, viral teaching and research room assists to test.Virus is influenza virus A type H3N2 and B-mode type strain, and cell is the primary human embryonic kidney cell.The drug cell toxicity test, select and cover with monolayer and WD HEKC plate, oral liquid and 7 concentration of syrup dilute liquid medicine of adding variable concentrations respectively, 3 brassboards of each concentration, put into 37 ℃ and cultivated 7 days, every day, the observation of cell pathological changes was calculated maximal non-toxic concentration TCO, median toxic concentration TC50, other establishes the cell contrast and does not add medicine.Result such as following table 4:
Table 4 drug cell toxicity test
TC90 TC50 TCO
Syrup 0.04 0.006 0.0006
Oral liquid 0.28 0.06 0.006
Annotate: TC90 is 90% poisoning concentration, and TC50 is 50% poisoning concentration, and TCO is a maximal non-toxic concentration; Its concentration contains crude drug with every milliliter and represents, i.e. g/ml.
Antivirus test, cytopathic-effect inhibition assay is selected eugonic HEKC, adds 100TCID50 virus liquid, 37 ℃ of 5%CO
2Adsorbed 2 hours, inhale virus removal, adding 7 concentration of 2 times of diluents of maximal non-toxic concentration liquid (1/2,1/4,1/8,1/16,1/32,1/64,1/128) cultivated 96 hours for 37 ℃, every day the observation of cell pathological changes, the record lesion degree, other establishes and does not add medicinal liquid matched group and experimental group while observation of cell pathological changes.Calculate 50% and suppress pathological changes concentration IC50, minimum effective drug concentration MIEC,
And therapeutic index TI sees the following form 5:
First type virus B virus
IC50 MIEC TI IC50 MIEC TI
Sugar 0.000038 0.000075 8 0.00038 0.00075 8
Oral liquid 0.00014 0.000168 32 0.00019 0.000375 16
The antiviral therapy index of the visible bavin silver of experimental result oral liquid improves than cold treating and cough relieving syrup.
Experimental example 2,The heat clearing away effect
1.1 the antipyretic effect to rat fever due to 2.4 dinitrophenol,DNP: 40 of 150-170g rats, ♂ ♀ half and half, be divided into four groups at random by the body weight sex, give bavin silver oral liquid 2.5g/kg, 5g/kg cold treating and cough relieving syrup 5g/kg respectively, matched group gives to irritate stomach with capacity water, the administration volume all is 1m, 1/100kg, administration 1 time.10min surveys normal body temperature behind the medicine, behind the 40min, give 2.5% 2.4 dinitrophenol,DNP 25mg/kgSC, rat temperature when injection back survey 0.5,1,2,4h, rat temperature and normal body temperature difference after statistical is respectively organized rat different time body temperature and injected 2.4 dinitrophenol,DNP the results are shown in Table 6,7:
Table 6 pair 2.4 dinitrophenol,DNP cause the X ± SD that influences of rat temperature
Dosage body temperature (℃)
The normal 0.5h 1h 2h 4h of group (g/kg)
Contrast 37.86 ± 0.47 38.88 ± 0.60 39.62 ± 0.66 39.81 ± 0.67 38.46 ± 0.56
Oral liquid 2.5 37.79 ± 0.43 38.76 ± 0.25 39.34 ± 0.29 39.24 ± 0.33* 38.28 ± 0.42
Oral liquid 5 37.87 ± 0.36 38.64 ± 0.75 38.80 ± 0.58 39.20 ± 0.20 38.68 ± 0.29
Syrup 5 37.76 ± 0.56 38.76 ± 0.77 39.33 ± 0.45 39.42 ± 0.59 38.36 ± 0.31
With the water matched group than * P＜0.05 and syrup group than Δ P＜0.05
Table 7 pair heating rat temperature changes difference influences X ± SD
Dosage body temperature (℃)
Group (g/kg) 0.5h 1h 2h 4h
Contrast 1.02 ± 0.33 1.76 ± .0.43 1.95 ± 0.53 0.8 ± 0.38
Oral liquid 2.5 0.97 ± 0.37 1.55 ± 0.37 1.55 ± 0.43 0.49 ± 0.43
Oral liquid 5 0.87 ± 0.39 0.93 ± 0.63 1.33 ± 0.30* 0.31 ± 0.35
Syrup 5 1.00 ± 0.34 1.57 ± 0.41 1.66 ± 0.40 0.60 ± 0.40
With the water matched group than * P＜0.01
The visible bavin silver of experimental result oral liquid has tangible antipyretic effect to 2.4 dinitrophenol,DNP fever rat, obviously reduces the body temperature peak.
2.2 the rabbit triple vaccine is caused the antipyretic effect of heating: 2-2.5kg rabbit (New Zealand's kind), Shandong Province's medical experiment animal center provides, quality certification Shandong real moving 950101.Through 40 of screening eligibles, ♂ ♀ dual-purpose, behind the jejunitas feedwater 12h, give typhoid fever, pay the typhoid fever first, second triple vaccine (Ministry of Public Health Shanghai biological study institute product, lot number 951012) record normal body temperature before the auricular vein injection 0.75ml/kg injection, injection back 60min surveys each rabbit body temperature, select temperature rising 0.8-1.2 ℃ 32, be divided into 4 groups at random, give bavin silver oral liquid 0.9g/kg, 1.8g/kg, syrup 1.8g/kg, matched group gives to be administered once with capacity water 4ml/kg, the record medicine after 1,3, the 5h rabbit body temperature, and calculate each rabbit body temperature and the normal temperature difference, result such as following table:
Table 8-1 influences X ± SD ℃ to fever in rabbit body temperature
Dosage body temperature (℃)
Group (g/kg) normal injection vaccine 1h 3h 5h
Contrast 39.04 ± 0.36 40.02 ± 0.42 40.40 ± 0.56 40.41 ± 0.82 39.46 ± 0.62
Oral liquid 0.98 39.11 ± 0.44 40.10 ± 0.37 40.21 ± 0.76 39.93 ± 0.74 39.37 ± 0.67
Oral liquid 1.8 39.07 ± 0.41 40.01 ± 0.26 40.12 ± 0.64 39.49 ± 0.78 39.18 ± 0.67
Syrup 1.8 39.12 ± 0.38 40.07 ± 0.44 40.18 ± 0.71 39.96 ± 0.67 39.36 ± 0.76
Respectively organize data in the table relatively by T check, behind each group injection vaccine 1 hour, its body temperature normal body temperature before the injection, P＜0.05.The water matched group feeds water its body temperature of each 1-3h still before pyrogenicity, illustrates that triple vaccine has tangible pyrogenic action.Three groups of administration rabbit, its body temperature of 2-4h is all on a declining curve behind the medicine.
Table 8-2 is to the antipyretic effect X ± SD of rabbit triple vaccine " heating "
Group dosage
Body temperature rise value ℃ behind the medicine
(g/kg) 1 2 3 4h
Water contrast 1.12 ± 0.21 0.81 ± 0.24 1.06 ± 0.26 0.74 ± 0.28
Oral liquid 0.9 0.94 ± 0.36 0.32 ± 0.41*, 0.53 ± 0.28*, 0.40 ± 0.34*
Oral liquid 1.8 0.88 ± 0.26 0.12 ± 0.47*, 0.36 ± 0.46*, 0.28 ± 0.44*
Syrup 1.8 0.94 ± 0.36 0.40 ± 0.41*, 0.54 ± 0.21*, 0.43 ± 0.41*
With the water matched group than * P＜0.05
The result shows that bavin silver oral liquid has the obvious cooling effect.
Experimental example 3.Antitussive action
3.1 drawing, mice ammonia coughs: screen 48 of qualified 20-22g mices, ♂ ♀ half and half, the same 1.1.1 of grouping administration, administration 1 time.Behind the administration 90min, mice is put into the 1L beaker, gives 60% ammonia, and ultrasonic atomizatio sprays into 15s, and the record mice coughs first and incubation period and 2min indegree occur, result such as following table:
Table 9 pair ammonia mice is drawn the antitussive effect X ± SD that coughs
Group dosage Mus is counted S number incubation period
Contrast 12 47.83 ± 23.46 11.83 ± 8.36
Oral liquid 3.68 12 80.16 ± 16.24***, 4.78 ± 2.41**
Oral liquid 7.36 12 88.48 ± 28.40***, 2.06 ± 2.35*** Δ Δs
Syrup 7.36 12 70.45 ± 26.22* 9.00 ± 7.55
With the water matched group than * P＜0.05**P＜0.01***P＜0.001 and syrup group than Δ Δ P＜0.01
The visible bavin silver of experimental result oral liquid has tangible antitussive effect, obviously is better than cold treating and cough relieving syrup with its effect under the dosage, reduces the cough number of times.
Cough experiment 3.2 Cavia porcellus 17.5% citric acid draws: screen 40 of qualified 150-200g Cavia porcelluss, ♂ ♀ dual-purpose is divided into 4 groups at random, give bavin silver oral liquid 1.5g/kg, 3g/kg respectively, cold treating and cough relieving syrup 3g/kg irritates stomach, and matched group gives to be administered once with capacity water, the administration volume all is 1ml/100g, behind the administration 90min, Cavia porcellus is put into 4L glass exsiccator, give 17.5% citric acid ultrasonic atomizatio spraying 15S, the record globefish belongs to cough first and cough number of times in incubation period and the 5min, result such as following table occur.
Table 10 pair Cavia porcellus citric acid draws the antitussive effect of coughing
Group dosage g/kg Mus is counted S cough incubation period number of times
Water contrasts 10 50.16 ± 16.32 15.88 ± 4.76
Oral liquid 1.5 10 76.48 ± 29.02* 7.47 ± 3.64** Δ
Oral liquid 3 10 70.00 ± 20.31* 7.84 ± 2.36** Δ
Syrup 3 10 63.89 ± 14.4 10.94 ± 2.47*
With the water matched group than * P＜0.05**P＜0.01, with the syrup group than Δ P＜0.05
Experimental result confirms that bavin silver oral liquid has tangible antitussive effect to irritable cough, obviously is better than cold treating and cough relieving syrup with its effect under the dosage.
Experimental example 4.Antiinflammatory action
4.1 influence to mice auricle swelling: 48 of 20-22g mices, ♂ ♀ dual-purpose is divided into 4 groups at random, the same 1.1.1 of dosage, administration 1 time, 20min after the administration, mouse right ear give 2% compound recipe Oleum Tiglii 20ul respectively and are coated with auricle both sides (positive and negative), be coated with back 4h, by diameter 9mm card punch, lay mice left and right sides auricle, by ten thousand/scales/electronic balance weighing, the auris dextra sheet heavily subtracts left auricle and heavily is the swelling degree, result such as following table.
Table 11 pair mice ear influence X ± SD
Group dosage g/kg Mus is counted the swelling degree
Contrast 12 27.07 ± 4.16
Oral liquid 3.68 12 17.08 ± 3.43*
Oral liquid 7.36 12 17.42 ± 4.27*
Syrup 7.36 12 18.55 ± 3.15
With matched group than * P＜0.05,
Experimental result confirms that when dose,equivalent (3.68g/kg) bavin silver oral liquid has obvious inhibitory action to acute exudative inflammation.
Experimental example 5.Facilitation to the mice nonspecific immunity: 56 of 8-20g mices, ♂ ♀ half and half, the same 1.1.1 of grouping administration, successive administration 8 days is behind the last administration 60min, the tail vein gives 20% Chinese prepared Chinese ink 0.1ml/10g, injection is respectively at injection back 2,17min, get blood 10ul by the ball venous plexus, add 2ml0.1%Na
2CO
3In the solution, in the 640nm place, 722 grating spectrophotometers are surveyed each specimen OD value, and by formula LogOD1-LogOD2/t2-t1 calculates mice carbon clearance rate K value.The results are shown in following table.
The influence of table 12 pair mice carbon clearance rate
Group dosage g/kg Mus number is cleaned up index K value (* 10
-3)
Contrast 14 2.40 ± 0.94
Oral liquid 3.68 14 4.76 ± 1.32 Δ * *
Oral liquid 7.36 14 5.27 ± 1.86 Δ * *
Syrup 7.3 14 3.48 ± 1.06*
With matched group than * P＜0.05**P＜0.001, with the syrup group than Δ P＜0.05
Experimental result confirms that bavin silver oral liquid has obvious facilitation to mice nonspecific immunity-netted cytophagous phagocytic function, obviously is better than cold treating and cough relieving syrup with its effect under the dosage.
The following example all can be realized the effect of above-mentioned experimental example:
Embodiment 1:
Radix Bupleuri 50g Flos Lonicerae 40g Radix Scutellariae 30g Radix Puerariae 25g
Herba Schizonepetae 25g Herba Artemisiae Annuae 40g Fructus Forsythiae 40g Semen Armeniacae Amarum 25g
Herba Menthae 40g Herba Houttuyniae 40g Radix Platycodonis 25g
More than ten simply, get Semen Armeniacae Amarum and be broken for coarse granule, with Radix Bupleuri, Flos Lonicerae, Herba Artemisiae Annuae, Fructus Forsythiae, Herba Schizonepetae, Herba Menthae, seven flavors such as Herba Houttuyniae, soaked 1 hour, add thermal distillation, collect distillate and distill again, collect re-distilled liquid, device is preserved in addition, medicinal residues and Radix Scutellariae, Radix Puerariae, three flavors such as Radix Platycodonis merge, and decoct with water each 2 hours three times, medicinal liquid after decocting liquid and the above-mentioned distillation merges, filter, filtrate concentrates, and adds ethanol, stir evenly, the supernatant decompression recycling ethanol is got in cold preservation 24 hours, concentrates, add above-mentioned re-distilled liquid, at last directly or add pharmaceutically acceptable excipient film-making agent through conventional operation.
Embodiment 2:
Radix Bupleuri 150g Flos Lonicerae 110g Radix Scutellariae 90g Radix Puerariae 75g
Herba Schizonepetae 75g Herba Artemisiae Annuae 110g Fructus Forsythiae 110g Semen Armeniacae Amarum 75g
Herba Menthae 110g Herba Houttuyniae 110g Radix Platycodonis 75g
More than ten simply, get Semen Armeniacae Amarum and be broken for coarse granule, with Radix Bupleuri, Flos Lonicerae, Herba Artemisiae Annuae, Fructus Forsythiae, Herba Schizonepetae, Herba Menthae, seven flavors such as Herba Houttuyniae, soaked 1 hour, add thermal distillation, collect distillate and distill again, collect re-distilled liquid, device is preserved in addition, medicinal residues and Radix Scutellariae, Radix Puerariae, three flavors such as Radix Platycodonis merge, and decoct with water each 2 hours three times, medicinal liquid after decocting liquid and the above-mentioned distillation merges, filter, filtrate concentrates, and adds ethanol, stir evenly, the supernatant decompression recycling ethanol is got in cold preservation 24 hours, concentrates, add above-mentioned re-distilled liquid, at last directly or add pharmaceutically acceptable excipient and make granule through conventional operation.
Embodiment 3:
Radix Bupleuri 80g Flos Lonicerae 60g Radix Scutellariae 50g Radix Puerariae 40g
Herba Schizonepetae 40g Herba Artemisiae Annuae 60g Fructus Forsythiae 60 Semen Armeniacae Amarum 40g
Herba Menthae 60g Herba Houttuyniae 60g Radix Platycodonis 40g
More than ten simply, get Semen Armeniacae Amarum and be broken for coarse granule, with Radix Bupleuri, Flos Lonicerae, Herba Artemisiae Annuae, Fructus Forsythiae, Herba Schizonepetae, Herba Menthae, seven flavors such as Herba Houttuyniae, soaked 1 hour, add thermal distillation, collect distillate and distill again, collect re-distilled liquid, device is preserved in addition, medicinal residues and Radix Scutellariae, Radix Puerariae, three flavors such as Radix Platycodonis merge, and decoct with water each 2 hours three times, medicinal liquid after decocting liquid and the above-mentioned distillation merges, filter, filtrate concentrates, and adds ethanol, stir evenly, the supernatant decompression recycling ethanol is got in cold preservation 24 hours, concentrates, add above-mentioned re-distilled liquid, at last directly or add pharmaceutically acceptable excipient and make capsule through conventional operation.
Embodiment 4:
Radix Bupleuri 120g Flos Lonicerae 90g Radix Scutellariae 70g Radix Puerariae 60g
Herba Schizonepetae 60g Herba Artemisiae Annuae 90g Fructus Forsythiae 90g Semen Armeniacae Amarum 60g
Herba Menthae 90g Herba Houttuyniae 90g Radix Platycodonis 60g
More than ten simply, get Semen Armeniacae Amarum and be broken for coarse granule, with Radix Bupleuri, Flos Lonicerae, Herba Artemisiae Annuae, Fructus Forsythiae, Herba Schizonepetae, Herba Menthae, seven flavors such as Herba Houttuyniae, soaked 1 hour, add thermal distillation, collect distillate and distill again, collect re-distilled liquid, device is preserved in addition, medicinal residues and Radix Scutellariae, Radix Puerariae, three flavors such as Radix Platycodonis merge, and decoct with water each 2 hours three times, medicinal liquid after decocting liquid and the above-mentioned distillation merges, filter, filtrate concentrates, and adds ethanol, stir evenly, the supernatant decompression recycling ethanol is got in cold preservation 24 hours, concentrates, add above-mentioned re-distilled liquid, at last directly or add pharmaceutically acceptable excipient and make capsule through conventional operation.
Embodiment 5:
Radix Bupleuri 100g Flos Lonicerae 75g Radix Scutellariae 60g Radix Puerariae 50g
Herba Schizonepetae 50g Herba Artemisiae Annuae 75g Fructus Forsythiae 75g Semen Armeniacae Amarum 50g
Herba Menthae 75g Herba Houttuyniae 75g Radix Platycodonis 50g
More than ten simply, get Semen Armeniacae Amarum and be broken for coarse granule, with Radix Bupleuri, Flos Lonicerae, Herba Artemisiae Annuae, Fructus Forsythiae, Herba Schizonepetae, Herba Menthae, seven flavors such as Herba Houttuyniae were soaked 1 hour, add thermal distillation, collect distillate 2875ml and distill again, collect re-distilled liquid 575ml, device is preserved in addition, medicinal residues and Radix Scutellariae, Radix Puerariae, three flavors such as Radix Platycodonis merge, decoct with water three times, each 2 hours, the medicinal liquid after decocting liquid and the above-mentioned distillation merged, filter, it is 1.11-1.14 that filtrate is concentrated into 50 ℃ of relative densities, and adding ethanol is 60% to containing the alcohol amount, stirs evenly, cold preservation 24 hours, get the supernatant decompression recycling ethanol, being concentrated into 50 ℃ of relative densities is 1.13-1.15, adds above-mentioned re-distilled liquid, stevioside 2g and sodium benzoate 3g, adjust the medicinal liquid total amount to 1000ml with distilled water, stir evenly, cold preservation 24 hours filters, with sodium hydroxide solution liquid PH value is adjusted into 5.5-7.5, fill, sterilization promptly gets oral liquid formulations.Every bottled 20ml, every bottle of suitable crude drug 14.7g, oral, each 20ml, 3 times on the one.
Embodiment 6:
Radix Bupleuri 100g Flos Lonicerae 75g Radix Scutellariae 60g Radix Puerariae 50g
Herba Schizonepetae 50g Herba Artemisiae Annuae 75g Fructus Forsythiae 75g Semen Armeniacae Amarum 50g
Herba Menthae 75g Herba Houttuyniae 75g
More than ten the flavor, get Semen Armeniacae Amarum and be broken for coarse granule, with Radix Bupleuri, Flos Lonicerae, Herba Artemisiae Annuae, Fructus Forsythiae, Herba Schizonepetae, Herba Menthae, seven flavors such as Herba Houttuyniae, soaked 1 hour, add thermal distillation, collect distillate and distill again, collect re-distilled liquid, device is preserved in addition, medicinal residues and Radix Scutellariae, two flavors such as Radix Puerariae merge, and decoct with water each 2 hours three times, medicinal liquid after decocting liquid and the above-mentioned distillation merges, filter, filtrate concentrates, and adds ethanol, stir evenly, the supernatant decompression recycling ethanol is got in cold preservation 24 hours, concentrates, add above-mentioned re-distilled liquid, at last directly or add pharmaceutically acceptable excipient and make granule through conventional operation.
Embodiment 7:
Radix Bupleuri 100g Flos Lonicerae 75g Radix Scutellariae 60g Radix Puerariae 50g
Herba Schizonepetae 50g Herba Artemisiae Annuae 75g Fructus Forsythiae 75g
More than seven the flavor, the five tastes such as Radix Bupleuri, Flos Lonicerae, Herba Artemisiae Annuae, Fructus Forsythiae, Herba Schizonepetae were soaked 1 hour, added thermal distillation, collecting distillate distills again, collect re-distilled liquid, device is preserved in addition, and two flavors such as medicinal residues and Radix Scutellariae, Radix Puerariae merge, decoct with water three times, each 2 hours, the medicinal liquid after decocting liquid and the above-mentioned distillation merged, and filtered, filtrate concentrates, add ethanol, stir evenly, cold preservation 24 hours, get the supernatant decompression recycling ethanol, concentrate, add above-mentioned re-distilled liquid, at last directly or add pharmaceutically acceptable excipient and make soft capsule through conventional operation.
Claims (8)
1, a kind of pharmaceutical composition for the treatment of anemopyretic cold is characterized in that this pharmaceutical composition made by following raw material medicaments:
Radix Bupleuri 50-150 weight portion Flos Lonicerae 40-110 weight portion Radix Scutellariae 30-90 weight portion
Radix Puerariae 25-75 weight portion Herba Schizonepetae 25-75 weight portion Herba Artemisiae Annuae 40-110 weight portion
Fructus Forsythiae 40-110 weight portion.
2, a kind of pharmaceutical composition for the treatment of anemopyretic cold is characterized in that this pharmaceutical composition made by following method:
Take by weighing following crude drug:
Radix Bupleuri 50-150 weight portion Flos Lonicerae 40-110 weight portion Radix Scutellariae 30-90 weight portion
Radix Puerariae 25-75 weight portion Herba Schizonepetae 25-75 weight portion Herba Artemisiae Annuae 40-110 weight portion
Fructus Forsythiae 40-110 weight portion Semen Armeniacae Amarum 25-75 weight portion Herba Menthae 40-110 weight portion
Herba Houttuyniae 40-110 weight portion Radix Platycodonis 25-75 weight portion;
Get Semen Armeniacae Amarum and be broken for coarse granule, with Radix Bupleuri, Flos Lonicerae, Herba Artemisiae Annuae, Fructus Forsythiae, Herba Schizonepetae, Herba Menthae, Herba Houttuyniae seven flavors were soaked 1 hour, added thermal distillation, collecting distillate distills again, collect re-distilled liquid, device is preserved in addition, medicinal residues and Radix Scutellariae, Radix Puerariae, Radix Platycodonis three flavors merge, decoct with water three times, each 2 hours, the medicinal liquid after decocting liquid and the above-mentioned distillation merged, and filtered, filtrate concentrates, add ethanol, stir evenly, cold preservation 24 hours, get the supernatant decompression recycling ethanol, concentrate, add above-mentioned re-distilled liquid, excipient direct through conventional operation at last or that adding is pharmaceutically accepted is made the dosage form of clinical acceptance.
3, pharmaceutical composition as claimed in claim 2 is characterized in that the crude drug of this pharmaceutical composition is:
Radix Bupleuri 80-120 weight portion Flos Lonicerae 60-90 weight portion Radix Scutellariae 50-70 weight portion
Radix Puerariae 40-60 weight portion Herba Schizonepetae 40-60 weight portion Herba Artemisiae Annuae 60-90 weight portion
Fructus Forsythiae 60-90 weight portion Radix Platycodonis 40-60 weight portion Semen Armeniacae Amarum 40-60 weight portion
Herba Menthae 60-90 weight portion Herba Houttuyniae 60-90 weight portion.
4, pharmaceutical composition as claimed in claim 3 is characterized in that the crude drug of this pharmaceutical composition is:
Radix Bupleuri 100 weight portion Flos Loniceraes 75 weight portion Radix Scutellariaes 60 weight portions
Radix Puerariae 50 weight portion Herba Schizonepetae 50 weight portion Herba Artemisiae Annuaes 75 weight portions
Fructus Forsythiae 75 weight portion Radix Platycodoniss 50 weight portion Semen Armeniacae Amarums 50 weight portions
Herba Menthae 75 weight portion Herba Houttuyniae 75 weight portions.
5, pharmaceutical composition as claimed in claim 1 is characterized in that adding excipient and makes the dosage form of clinical acceptance in this pharmaceutical composition.
6,, it is characterized in that said excipient is one or more in the middle of solvent, coloring agent, correctives, dispersant, binding agent, thickening agent, lubricant, diluent, disintegrating agent, the antiseptic according to the said pharmaceutical composition of claim 5.
7, pharmaceutical composition as claimed in claim 5, the dosage form that it is characterized in that this pharmaceutical composition are pill, tablet, granule, oral liquid, capsule, unguentum, Emulsion, masticatory, injection or middle medicine film.
8, the application of pharmaceutical composition as claimed in claim 1 in the medicine of preparation treatment anemopyretic cold.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031001882A CN1207033C (en) | 2003-01-09 | 2003-01-09 | Traditional Chinese medicine composition for curing wind-heat type cold and its preparing method |
| AU2003278405A AU2003278405A1 (en) | 2003-01-07 | 2003-10-22 | Electric cable storage device |
| PCT/IB2003/004656 WO2004062054A1 (en) | 2003-01-07 | 2003-10-22 | Electric cable storage device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031001882A CN1207033C (en) | 2003-01-09 | 2003-01-09 | Traditional Chinese medicine composition for curing wind-heat type cold and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1425449A CN1425449A (en) | 2003-06-25 |
| CN1207033C true CN1207033C (en) | 2005-06-22 |
Family
ID=4789791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031001882A Expired - Lifetime CN1207033C (en) | 2003-01-07 | 2003-01-09 | Traditional Chinese medicine composition for curing wind-heat type cold and its preparing method |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1207033C (en) |
| AU (1) | AU2003278405A1 (en) |
| WO (1) | WO2004062054A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770074A (en) * | 2016-04-20 | 2016-07-20 | 山东明仁福瑞达制药股份有限公司 | Traditional Chinese medicine composition for treating wind-heat common cold and preparation method thereof |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202004017665U1 (en) * | 2004-11-15 | 2005-02-03 | Heinrich Kopp Gmbh | Device for winding a cable or a tubular article |
| CN100409862C (en) * | 2005-03-01 | 2008-08-13 | 重庆大易科技投资有限公司 | Chinese medicinal composition for treating viral infection of upper respiratory tract and preparing process thereof |
| CN1985921B (en) * | 2005-12-20 | 2011-04-06 | 广州王老吉药业股份有限公司 | Chinese medicine composition for treating common cold and its preparing method |
| CN100348231C (en) * | 2006-03-06 | 2007-11-14 | 成都厚发科技开发有限公司 | Medicine composition for resisting exogenous cold and high fever, and its preparing method |
| WO2007112477A1 (en) * | 2006-04-03 | 2007-10-11 | Tks Electrics Pty Ltd | Cable storage device |
| CN101152202B (en) * | 2007-09-29 | 2010-11-24 | 中国药科大学 | Pharmaceutical composition for treating apparatus respiratorius disease and method for preparing the same |
| CN102188533A (en) * | 2010-03-03 | 2011-09-21 | 鲁南厚普制药有限公司 | Oral liquid preparation for curing wind-heat type cold and preparation method thereof |
| AT511018B1 (en) * | 2011-01-18 | 2013-04-15 | Feller Gmbh | KABELTROMMEL CABLE |
| CN103083584A (en) * | 2011-11-04 | 2013-05-08 | 陈良鉴 | Traditional Chinese medicine for treating influenza |
| FR3023075A1 (en) * | 2014-06-27 | 2016-01-01 | Commissariat Energie Atomique | ELECTRICAL CONNECTION SHEET |
| FR3023055B1 (en) * | 2014-06-27 | 2018-02-23 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | ELECTRIC CABLE ROLLER DEVICE |
| CN104367941A (en) * | 2014-11-03 | 2015-02-25 | 山东瑞康生命科技有限公司 | Preparation method of traditional Chinese medicinal preparation for treating singapore hemorrhagic fever |
| CN105250920A (en) * | 2015-11-10 | 2016-01-20 | 北京市祖国红医疗科技中心（有限合伙） | Traditional Chinese medicine for treating respiratory diseases caused by haze and preparation method and application thereof |
| CN106334040A (en) * | 2016-08-31 | 2017-01-18 | 安徽省润生医药股份有限公司 | Medicinal composition for treating wind-heat type common cold, preparation method thereof and preparation |
| CN111228357A (en) * | 2018-11-28 | 2020-06-05 | 鲁南制药集团股份有限公司 | Chaiyin micro-pill preparation and preparation method thereof |
| CN111297969A (en) * | 2020-03-25 | 2020-06-19 | 鲁南制药集团股份有限公司 | Application of Chaihingzhi preparation in preparing anti-coronavirus medicine and its preparation method |
| CN113521210B (en) * | 2020-04-17 | 2024-04-16 | 天士力医药集团股份有限公司 | Chinese medicinal composition containing herba Moslae |
| CN111450166A (en) * | 2020-05-14 | 2020-07-28 | 鲁南制药集团股份有限公司 | New use of Chaihingzhi in resisting enterovirus |
| CN112843184A (en) * | 2020-12-10 | 2021-05-28 | 石门县中医医院 | Pharmaceutical composition for treating wind-heat type common cold and application thereof |
| CN114917298B (en) * | 2022-05-07 | 2023-10-20 | 森隆药业有限公司 | Pharmaceutical composition for treating pneumonia and preparation method thereof |
| CN115227770A (en) * | 2022-07-23 | 2022-10-25 | 安阳市中医院 | Traditional Chinese medicine composition for treating exogenous fever of children |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE840867C (en) * | 1950-01-03 | 1952-06-05 | Siemens Ag | Electrical cable with non-metallic protective sheath |
| CH278388A (en) * | 1950-04-12 | 1951-10-15 | Zanoni Fritz | Device on electrical cables. |
| DE1765452U (en) * | 1956-05-31 | 1958-04-24 | Siemens Ag | ELECTRIC CABLE WITH AN OUTER SHEATH MADE OF PLASTIC MADE OF INJECTION METHOD. |
| DE3401026A1 (en) * | 1984-01-13 | 1985-07-18 | Hugo Brennenstuhl GmbH & Co KG, 7400 Tübingen | PORTABLE CABLE DRUM |
| IT234264Y1 (en) * | 1994-12-01 | 2000-03-09 | Cavis Srl | STRUCTURE OF CONTINUOUS PROTECTIVE SHEATH FOR COATING A BAND OF ELECTRIC CABLES |
| DE19804715A1 (en) * | 1998-02-06 | 1999-08-12 | Murrplastik Systemtechnik Gmbh | Electric cable |
| JP2001031332A (en) * | 1999-07-23 | 2001-02-06 | Mitsubishi Cable Ind Ltd | Feeding drum |
| JP2001357728A (en) * | 2000-06-13 | 2001-12-26 | Sumitomo Wiring Syst Ltd | Electric wire and its preparing method |
| JP2002193555A (en) * | 2000-12-27 | 2002-07-10 | Fujikura Ltd | Feeder cable reeling device for movable equipment and cable reel |
-
2003
- 2003-01-09 CN CNB031001882A patent/CN1207033C/en not_active Expired - Lifetime
- 2003-10-22 WO PCT/IB2003/004656 patent/WO2004062054A1/en not_active Application Discontinuation
- 2003-10-22 AU AU2003278405A patent/AU2003278405A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770074A (en) * | 2016-04-20 | 2016-07-20 | 山东明仁福瑞达制药股份有限公司 | Traditional Chinese medicine composition for treating wind-heat common cold and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1425449A (en) | 2003-06-25 |
| AU2003278405A1 (en) | 2004-07-29 |
| WO2004062054A1 (en) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1207033C (en) | Traditional Chinese medicine composition for curing wind-heat type cold and its preparing method | |
| CN101040915A (en) | Method for preparing a Shuanhuanglian injection and the component detecting method | |
| CN1248725C (en) | Compound traditional Chinese medicine preparation for acute , chronic pharyngitis and tonsillitis | |
| CN1772079A (en) | Medicine for treating upper respiratory tract infection and preparation method thereof | |
| CN1943675A (en) | Tibetan medicinal composition for expectorant, antitussive, antiasthmatic and its preparation method | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN101053600A (en) | Medicinal composition for treating cough and preparation method and application thereof | |
| CN1323668C (en) | Pharmaceutical compositions and its application | |
| CN1903254A (en) | Compound medicine for treating wind-heat type cold and preparing method thereof | |
| CN1606979A (en) | Effect of scutellarein as antifebrile, analgesic, antiphlogistic, antibiotic and antiviral agent | |
| CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN100339101C (en) | Preparation and usage of | |
| CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN1814221A (en) | Chinese medicine composition for treating urethra infection and preparing method | |
| CN1211094C (en) | Medicine for treating pulmonary tuberculosis | |
| CN1323681C (en) | Compound preparation for upper respiratory tract infection and its use in production of medicines | |
| CN1947756A (en) | Formula of seven herbs medicine composition for relieving internal heat and invigorating blood circulation, its prepn. process and use | |
| CN1742845A (en) | Medicine for treating rheumatism and rheumatoid diseases and preparing method | |
| CN1589892A (en) | Medicinal composition for treating acute, chronic pharyngolaryngitis and its preparation method | |
| CN1287811C (en) | Lung clearing preparation for treating respiratory virus infection diseases | |
| CN1813916A (en) | Compound chinese medicine formulation for treating common cold and its preparing process | |
| CN1220515C (en) | Medicine for treating throat disease | |
| CN1903343A (en) | Medicine composition for treating biliary tract calculus, prepn. method and use thereof | |
| CN1602945A (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN1634413A (en) | Bastard speedwell injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: LUNAN PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME OR ADDRESS: LUNAN PHARMACY CO. LTD. |
|
| CP03 | Change of name, title or address |
Address after: 276005 No. 209 Hongqi Road, Shandong, Linyi Patentee after: LUNAN PHARMACEUTICAL Group Corp. Address before: 276003 No. 107, No. 1, Linxi, Shandong, Linyi Patentee before: Lunan Pharmaceutical Co.,Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000515 Denomination of invention: Chinese medicine composition for treating wind-heat type common cold Granted publication date: 20050622 License type: Exclusive License Open date: 20030625 Record date: 20100909 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000515 Date of cancellation: 20131016 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20030625 Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2013370000262 Denomination of invention: Chinese medicine composition for treating wind-heat type common cold Granted publication date: 20050622 License type: Exclusive License Record date: 20131210 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161230 Address after: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee after: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Address before: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee before: LUNAN PHARMACEUTICAL Group Corp. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050622 |